"","total","expected","hits","Raw p","Holm p","FDR"
"Amino acid transport across the plasma membrane",32,0.314,18,4.4e-30,1.46e-26,1.46e-26
"Amino acid transport defects (IEMs)",27,0.265,17,1.37e-29,4.54e-26,2.27e-26
"Transcription/Translation",25,0.245,16,5.46e-28,1.81e-24,6.04e-25
"Na+/Cl- dependent neurotransmitter transporters",32,0.314,17,8.93e-28,2.96e-24,7.4e-25
"Transport of inorganic cations/anions and amino acids/oligopeptides",52,0.51,19,3.65e-27,1.21e-23,2.42e-24
"Amino acid metabolism",109,1.07,23,5.81e-27,1.92e-23,3.21e-24
"SLC-mediated transmembrane transport",155,1.52,25,1.98e-26,6.56e-23,9.39e-24
"Transport of bile salts and organic acids, metal ions and amine compounds",76,0.746,20,2.52e-25,8.35e-22,1.05e-22
"Transport of small molecules",208,2.04,25,4.31e-23,1.43e-19,1.59e-20
"Cytosolic tRNA aminoacylation",66,0.648,17,3.28e-21,1.09e-17,9.08e-19
"tRNA Aminoacylation",66,0.648,17,3.28e-21,1.09e-17,9.08e-19
"Mitochondrial tRNA aminoacylation",66,0.648,17,3.28e-21,1.09e-17,9.08e-19
"Metabolism of amino acids and derivatives",283,2.78,26,4.46e-21,1.47e-17,1.14e-18
"Variant SLC6A14 may confer susceptibility towards obesity",15,0.147,11,2.6e-20,8.58e-17,6.16e-18
"SLC transporter disorders",80,0.785,17,1.22e-19,4.04e-16,2.71e-17
"Translation",83,0.814,17,2.42e-19,7.98e-16,5.01e-17
"Defective SLC6A19 causes Hartnup disorder (HND)",13,0.128,10,7.31e-19,2.41e-15,1.43e-16
"Disorders of transmembrane transporters",98,0.961,17,4.99e-18,1.64e-14,9.18e-16
"Biochemical pathways: part I",445,4.37,26,4.74e-16,1.56e-12,8.27e-14
"Glucose homeostasis",21,0.206,10,8.54e-16,2.82e-12,1.42e-13
"Tryptophan catabolism",33,0.324,11,3.27e-15,1.08e-11,5.05e-13
"Amikacin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Arbekacin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Azithromycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Chloramphenicol Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Clarithromycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Clindamycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Clomocycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Demeclocycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Doxycycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Erythromycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Gentamicin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Josamycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Kanamycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Lincomycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Lymecycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Methacycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Minocycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Neomycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Netilmicin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Oxytetracycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Paromomycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Rolitetracycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Roxithromycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Spectinomycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Streptomycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Telithromycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Tetracycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Tigecycline Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Tobramycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Troleandomycin Action Pathway",17,0.167,9,7.77e-15,2.56e-11,5.05e-13
"Metabolism of proteins",295,2.89,21,2.89e-14,9.44e-11,1.84e-12
"mRNA, protein, and metabolite inducation pathway by cyclosporin A",13,0.128,8,5.27e-14,1.72e-10,3.3e-12
"Biomarkers for urea cycle disorders",22,0.216,8,1.23e-11,4.01e-08,7.55e-10
"Urea cycle and metabolism of amino groups",34,0.334,9,1.49e-11,4.85e-08,8.97e-10
"Metabolism",1370,13.4,34,7.07e-11,2.31e-07,4.19e-09
"Trans-sulfuration, one-carbon metabolism and related pathways",58,0.569,9,2.55e-09,8.32e-06,1.49e-07
"Biogenic amine synthesis",17,0.167,6,7.04e-09,2.29e-05,4.02e-07
"Argininemia",22,0.216,6,4.09e-08,0.000133,2.15e-06
"Argininosuccinic Aciduria",22,0.216,6,4.09e-08,0.000133,2.15e-06
"Carbamoyl Phosphate Synthetase Deficiency",22,0.216,6,4.09e-08,0.000133,2.15e-06
"Citrullinemia Type I",22,0.216,6,4.09e-08,0.000133,2.15e-06
"Ornithine Transcarbamylase Deficiency (OTC Deficiency)",22,0.216,6,4.09e-08,0.000133,2.15e-06
"Glycine, serine and threonine metabolism",56,0.549,8,4.29e-08,0.000139,2.22e-06
"Nitrogen metabolism",25,0.245,6,9.5e-08,0.000309,4.85e-06
"G alpha (q) signalling events",63,0.618,8,1.11e-07,0.000361,5.54e-06
"Disease",470,4.61,18,1.12e-07,0.000364,5.54e-06
"Spermidine and Spermine Biosynthesis",14,0.137,5,1.33e-07,0.000434,6.41e-06
"Urea cycle and related diseases",14,0.137,5,1.33e-07,0.000434,6.41e-06
"Urea cycle and associated pathways",30,0.294,6,3.07e-07,0.000998,1.46e-05
"Arginine and proline metabolism",49,0.481,7,3.29e-07,0.00107,1.54e-05
"T cell modulation in pancreatic cancer",8,0.0785,4,5.45e-07,0.00177,2.51e-05
"Creatine pathway",18,0.177,5,5.55e-07,0.0018,2.52e-05
"Alanine, aspartate and glutamate metabolism",58,0.569,7,1.08e-06,0.0035,4.84e-05
"Metabolism of polyamines",21,0.206,5,1.29e-06,0.00418,5.7e-05
"Urea cycle",22,0.216,5,1.66e-06,0.00537,7.23e-05
"MECP2 and associated Rett syndrome",11,0.108,4,2.51e-06,0.00815,0.000108
"Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)",44,0.432,6,3.3e-06,0.0107,0.000124
"Creatine deficiency, guanidinoacetate methyltransferase deficiency",44,0.432,6,3.3e-06,0.0107,0.000124
"Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)",44,0.432,6,3.3e-06,0.0107,0.000124
"Hyperornithinemia with gyrate atrophy (HOGA)",44,0.432,6,3.3e-06,0.0107,0.000124
"Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome]",44,0.432,6,3.3e-06,0.0107,0.000124
"Hyperprolinemia Type I",44,0.432,6,3.3e-06,0.0107,0.000124
"Hyperprolinemia Type II",44,0.432,6,3.3e-06,0.0107,0.000124
"L-arginine:glycine amidinotransferase deficiency",44,0.432,6,3.3e-06,0.0107,0.000124
"Ornithine Aminotransferase Deficiency (OAT Deficiency)",44,0.432,6,3.3e-06,0.0107,0.000124
"Prolidase Deficiency (PD)",44,0.432,6,3.3e-06,0.0107,0.000124
"Prolinemia Type II",44,0.432,6,3.3e-06,0.0107,0.000124
"Defective SLC3A1 causes cystinuria (CSNU)",4,0.0392,3,3.49e-06,0.0113,0.000129
"Defective SLC7A9 causes cystinuria (CSNU)",4,0.0392,3,3.49e-06,0.0113,0.000129
"Protein repair",12,0.118,4,3.74e-06,0.0121,0.000136
"Methionine de novo and salvage pathway",48,0.471,6,5.57e-06,0.018,0.000201
"3-Phosphoglycerate dehydrogenase deficiency",49,0.481,6,6.3e-06,0.0203,0.000213
"Dihydropyrimidine Dehydrogenase Deficiency (DHPD)",49,0.481,6,6.3e-06,0.0203,0.000213
"Dimethylglycine Dehydrogenase Deficiency",49,0.481,6,6.3e-06,0.0203,0.000213
"Hyperglycinemia, non-ketotic",49,0.481,6,6.3e-06,0.0203,0.000213
"Non Ketotic Hyperglycinemia",49,0.481,6,6.3e-06,0.0203,0.000213
"Sarcosinemia",49,0.481,6,6.3e-06,0.0203,0.000213
"Sudden infant death syndrome (SIDS) susceptibility pathways",14,0.137,4,7.47e-06,0.024,0.00025
"Methionine Metabolism",51,0.5,6,8e-06,0.0257,0.000265
"Canavan Disease",30,0.294,5,8.46e-06,0.0272,0.000275
"Hypoacetylaspartia",30,0.294,5,8.46e-06,0.0272,0.000275
"Aspartate Metabolism",31,0.304,5,1e-05,0.0322,0.000322
"Creatine metabolism",15,0.147,4,1.01e-05,0.0325,0.000322
"Metabolism overview",116,1.14,8,1.25e-05,0.0401,0.000394
"GPCR downstream signalling",156,1.53,9,1.43e-05,0.0459,0.000444
"Signal Transduction",345,3.38,13,1.43e-05,0.0459,0.000444
"Ras activation upon Ca2+ influx through NMDA receptor",6,0.0589,3,1.72e-05,0.0552,0.000519
"Negative regulation of NMDA receptor-mediated neuronal transmission",6,0.0589,3,1.72e-05,0.0552,0.000519
"Long-term potentiation",6,0.0589,3,1.72e-05,0.0552,0.000519
"Amino acid metabolism pathway excerpt: histidine catabolism extension",17,0.167,4,1.74e-05,0.0557,0.000519
"Glutaminolysis and Cancer",35,0.343,5,1.86e-05,0.0596,0.00055
"Amine Oxidase reactions",18,0.177,4,2.22e-05,0.0711,0.000651
"Cystathionine Beta-Synthase Deficiency",37,0.363,5,2.46e-05,0.0788,0.00068
"Glycine N-methyltransferase Deficiency",37,0.363,5,2.46e-05,0.0788,0.00068
"Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation type",37,0.363,5,2.46e-05,0.0788,0.00068
"Hypermethioninemia",37,0.363,5,2.46e-05,0.0788,0.00068
"Methionine Adenosyltransferase Deficiency",37,0.363,5,2.46e-05,0.0788,0.00068
"Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)",37,0.363,5,2.46e-05,0.0788,0.00068
"S-Adenosylhomocysteine (SAH) Hydrolase Deficiency",37,0.363,5,2.46e-05,0.0788,0.00068
"Unblocking of NMDA receptors, glutamate binding and activation",7,0.0687,3,2.99e-05,0.0956,0.00082
"Cysteine and methionine catabolism",39,0.383,5,3.2e-05,0.102,0.000871
"Phenylalanine metabolism",20,0.196,4,3.46e-05,0.111,0.000933
"Alanine and aspartate metabolism",21,0.206,4,4.25e-05,0.136,0.00114
"Pyrimidine metabolism and related diseases",43,0.422,5,5.2e-05,0.166,0.00138
"Glutamate and glutamine metabolism",23,0.226,4,6.19e-05,0.198,0.00162
"Tryptophan catabolism leading to NAD+ production",23,0.226,4,6.19e-05,0.198,0.00162
"Nitric oxide metabolism in cystic fibrosis",9,0.0883,3,7.08e-05,0.226,0.00183
"Aspartate and asparagine metabolism",24,0.235,4,7.38e-05,0.235,0.00187
"NAD biosynthesis II (from tryptophan)",24,0.235,4,7.38e-05,0.235,0.00187
"Serine metabolism",24,0.235,4,7.38e-05,0.235,0.00187
"Transmission across Chemical Synapses",77,0.755,6,8.72e-05,0.278,0.00213
"Neuronal System",77,0.755,6,8.72e-05,0.278,0.00213
"Metabolism of nitric oxide: NOS3 activation and regulation",25,0.245,4,8.72e-05,0.278,0.00213
"eNOS activation",25,0.245,4,8.72e-05,0.278,0.00213
"Neurotransmitter receptors and postsynaptic signal transmission",25,0.245,4,8.72e-05,0.278,0.00213
"Protein-protein interactions at synapses",2,0.0196,2,9.4e-05,0.299,0.00224
"Synaptic adhesion-like molecules",2,0.0196,2,9.4e-05,0.299,0.00224
"SALM protein interactions at the synapse",2,0.0196,2,9.4e-05,0.299,0.00224
"Carboxyterminal post-translational modifications of tubulin",10,0.0981,3,1e-04,0.319,0.00236
"CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling",10,0.0981,3,1e-04,0.319,0.00236
"Neuroinflammation and glutamatergic signaling",26,0.255,4,0.000102,0.325,0.00239
"Organic cation transport",27,0.265,4,0.000119,0.379,0.00275
"Extra-nuclear estrogen signaling",27,0.265,4,0.000119,0.379,0.00275
"Miscellaneous transport and binding events",11,0.108,3,0.000137,0.435,0.00312
"PAOs oxidise polyamines to amines",11,0.108,3,0.000137,0.435,0.00312
"22q11.2 copy number variation syndrome",28,0.275,4,0.000138,0.438,0.00312
"Tryptophan metabolism",53,0.52,5,0.000144,0.457,0.00321
"G alpha (q) signaling events",53,0.52,5,0.000144,0.457,0.00321
"GPCR ligand binding",211,2.07,9,0.000156,0.493,0.00344
"Disorders of folate metabolism and transport",29,0.285,4,0.000159,0.504,0.0035
"Peptide hormone metabolism",56,0.549,5,0.000188,0.595,0.0041
"Class C/3 (Metabotropic glutamate/pheromone receptors)",57,0.559,5,0.000205,0.647,0.00443
"Biosynthesis and regeneration of tetrahydrobiopterin and catabolism of phenylalanine",31,0.304,4,0.000208,0.658,0.00448
"Post NMDA receptor activation events",13,0.128,3,0.000235,0.742,0.00492
"Interconversion of polyamines",13,0.128,3,0.000235,0.742,0.00492
"Glycine metabolism",13,0.128,3,0.000235,0.742,0.00492
"Pleural mesothelioma",13,0.128,3,0.000235,0.742,0.00492
"ESR-mediated signaling",33,0.324,4,0.000267,0.842,0.00556
"Defective SLC7A7 causes lysinuric protein intolerance (LPI)",3,0.0294,2,0.00028,0.885,0.00577
"Serotonin transporter activity",3,0.0294,2,0.00028,0.885,0.00577
"Trans-sulfuration pathway",14,0.137,3,0.000297,0.936,0.00607
"Organic cation/anion/zwitterion transport",34,0.334,4,3e-04,0.946,0.0061
"Signaling by GPCR",236,2.32,9,0.000363,1,0.00722
"Lactic Acidemia",15,0.147,3,0.000368,1,0.00722
"Primary Hyperoxaluria Type I",15,0.147,3,0.000368,1,0.00722
"Pyruvate Carboxylase Deficiency",15,0.147,3,0.000368,1,0.00722
"NO/cGMP/PKG mediated neuroprotection",15,0.147,3,0.000368,1,0.00722
"Glyoxylate metabolism",15,0.147,3,0.000368,1,0.00722
"Metabolism of amine-derived hormones",36,0.353,4,0.000376,1,0.00733
"Metabolism of vitamins and cofactors",189,1.85,8,0.000403,1,0.00781
"Branched-chain amino acid catabolism",37,0.363,4,0.000418,1,0.00806
"VEGFR2 mediated vascular permeability",16,0.157,3,0.00045,1,0.00863
"Glyoxylate metabolism and glycine degradation",38,0.373,4,0.000464,1,0.00879
"Metabolic reprogramming in colon cancer",38,0.373,4,0.000464,1,0.00879
"2-Hydroxyglutric Aciduria (D And L Form)",39,0.383,4,0.000513,1,0.00941
"4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency",39,0.383,4,0.000513,1,0.00941
"Glutamate Metabolism",39,0.383,4,0.000513,1,0.00941
"Homocarnosinosis",39,0.383,4,0.000513,1,0.00941
"Hyperinsulinism-Hyperammonemia Syndrome",39,0.383,4,0.000513,1,0.00941
"Succinic semialdehyde dehydrogenase deficiency",39,0.383,4,0.000513,1,0.00941
"Glutathione metabolism",17,0.167,3,0.000543,1,0.00968
"5-oxoprolinase deficiency",17,0.167,3,0.000543,1,0.00968
"Gamma-glutamyl-transpeptidase deficiency",17,0.167,3,0.000543,1,0.00968
"Gamma-Glutamyltransferase Deficiency",17,0.167,3,0.000543,1,0.00968
"Glutathione Synthetase Deficiency",17,0.167,3,0.000543,1,0.00968
"Proton-coupled neutral amino acid transporters",4,0.0392,2,0.000557,1,0.00982
"Alanine metabolism",4,0.0392,2,0.000557,1,0.00982
"Developmental Biology",40,0.392,4,0.000566,1,0.00994
"Activation of NMDA receptors and postsynaptic events",18,0.177,3,0.000647,1,0.0113
"Axon guidance",20,0.196,3,0.000892,1,0.0153
"Nervous system development",20,0.196,3,0.000892,1,0.0153
"Sarcosine Oncometabolite Pathway",20,0.196,3,0.000892,1,0.0153
"Defective SLC1A3 causes episodic ataxia 6 (EA6)",5,0.0491,2,0.000922,1,0.0157
"Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA)",5,0.0491,2,0.000922,1,0.0157
"Neurotransmitter release cycle",46,0.451,4,0.000969,1,0.0162
"RAF/MAP kinase cascade",46,0.451,4,0.000969,1,0.0162
"MAPK family signaling cascades",46,0.451,4,0.000969,1,0.0162
"MAPK1/MAPK3 signaling",46,0.451,4,0.000969,1,0.0162
"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",21,0.206,3,0.00103,1,0.017
"Incretin synthesis, secretion, and inactivation",21,0.206,3,0.00103,1,0.017
"Ethanol effects on histone modifications",21,0.206,3,0.00103,1,0.017
"Signaling by Nuclear Receptors",50,0.491,4,0.00133,1,0.0209
"Free fatty acid receptors",23,0.226,3,0.00136,1,0.0209
"Neurotransmitter disorders",23,0.226,3,0.00136,1,0.0209
"Methionine metabolism leading to sulfur amino acids and related disorders",23,0.226,3,0.00136,1,0.0209
"Agmatine biosynthesis",6,0.0589,2,0.00137,1,0.0209
"Amino acids regulate mTORC1",6,0.0589,2,0.00137,1,0.0209
"Valine, leucine and isoleucine degradation",51,0.5,4,0.00143,1,0.0209
"Metabolic disorders of biological oxidation enzymes",51,0.5,4,0.00143,1,0.0209
"2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency",51,0.5,4,0.00143,1,0.0209
"3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency",51,0.5,4,0.00143,1,0.0209
"3-hydroxyisobutyric acid dehydrogenase deficiency",51,0.5,4,0.00143,1,0.0209
"3-hydroxyisobutyric aciduria",51,0.5,4,0.00143,1,0.0209
"3-Methylcrotonyl Coa Carboxylase Deficiency Type I",51,0.5,4,0.00143,1,0.0209
"3-Methylglutaconic Aciduria Type I",51,0.5,4,0.00143,1,0.0209
"3-Methylglutaconic Aciduria Type III",51,0.5,4,0.00143,1,0.0209
"3-Methylglutaconic Aciduria Type IV",51,0.5,4,0.00143,1,0.0209
"Beta-Ketothiolase Deficiency",51,0.5,4,0.00143,1,0.0209
"Isobutyryl-coa dehydrogenase deficiency",51,0.5,4,0.00143,1,0.0209
"Isovaleric acidemia",51,0.5,4,0.00143,1,0.0209
"Isovaleric Aciduria",51,0.5,4,0.00143,1,0.0209
"Maple Syrup Urine Disease",51,0.5,4,0.00143,1,0.0209
"Methylmalonate Semialdehyde Dehydrogenase Deficiency",51,0.5,4,0.00143,1,0.0209
"Methylmalonic Aciduria",51,0.5,4,0.00143,1,0.0209
"Propionic Acidemia",51,0.5,4,0.00143,1,0.0209
"Metabolism of water-soluble vitamins and cofactors",129,1.27,6,0.00143,1,0.0209
"Metabolism of folate and pterines",24,0.235,3,0.00154,1,0.0222
"Tyrosinemia Type 2 (or Richner-Hanhart syndrome)",24,0.235,3,0.00154,1,0.0222
"Tyrosinemia Type 3 (TYRO3)",24,0.235,3,0.00154,1,0.0222
"One-carbon metabolism",25,0.245,3,0.00174,1,0.0247
"Metabolic pathways of fibroblasts",25,0.245,3,0.00174,1,0.0247
"Cerebral organic acidurias, including diseases",25,0.245,3,0.00174,1,0.0247
"Insulin processing",7,0.0687,2,0.00191,1,0.0267
"LTC4-CYSLTR mediated IL4 production",7,0.0687,2,0.00191,1,0.0267
"Malate-Aspartate Shuttle",7,0.0687,2,0.00191,1,0.0267
"Effects of nitric oxide",7,0.0687,2,0.00191,1,0.0267
"Synaptic vesicle pathway",7,0.0687,2,0.00191,1,0.0267
"Omega-9 fatty acid synthesis",27,0.265,3,0.00218,1,0.0303
"beta-Alanine metabolism",28,0.275,3,0.00243,1,0.0327
"Phenylalanine and Tyrosine Metabolism",28,0.275,3,0.00243,1,0.0327
"Signaling by VEGF",28,0.275,3,0.00243,1,0.0327
"VEGFA-VEGFR2 Pathway",28,0.275,3,0.00243,1,0.0327
"Carnosinuria, carnosinemia",28,0.275,3,0.00243,1,0.0327
"GABA-Transaminase Deficiency",28,0.275,3,0.00243,1,0.0327
"Ureidopropionase Deficiency",28,0.275,3,0.00243,1,0.0327
"Glucose-Alanine Cycle",8,0.0785,2,0.00253,1,0.0338
"Major receptors targeted by epinephrine and norepinephrine",8,0.0785,2,0.00253,1,0.0338
"Physico-chemical features and toxicity-associated pathways",8,0.0785,2,0.00253,1,0.0338
"Folate metabolism",61,0.598,4,0.00279,1,0.037
"Biological oxidations",317,3.11,9,0.003,1,0.0396
"Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS)",9,0.0883,2,0.00324,1,0.0423
"Biosynthesis of maresin conjugates in tissue regeneration (MCTR)",9,0.0883,2,0.00324,1,0.0423
"Carnosine metabolism of glial cells",9,0.0883,2,0.00324,1,0.0423
"Sulfur amino acid metabolism",65,0.638,4,0.00351,1,0.0457
"Metabolism of ingested SeMet, Sec, MeSec into H2Se",33,0.324,3,0.0039,1,0.0505
"Leucine, isoleucine and valine metabolism",67,0.657,4,0.00392,1,0.0505
"D-Arginine and D-Ornithine Metabolism",10,0.0981,2,0.00402,1,0.0505
"Transport of fatty acids",10,0.0981,2,0.00402,1,0.0505
"EPH-Ephrin signaling",10,0.0981,2,0.00402,1,0.0505
"EPHB-mediated forward signaling",10,0.0981,2,0.00402,1,0.0505
"Cellular response to starvation",10,0.0981,2,0.00402,1,0.0505
"Amyotrophic lateral sclerosis (ALS)",10,0.0981,2,0.00402,1,0.0505
"Neuroinflammation",10,0.0981,2,0.00402,1,0.0505
"Fatty Acid Biosynthesis",34,0.334,3,0.00425,1,0.0532
"Fabry disease",35,0.343,3,0.00462,1,0.0568
"Gaucher Disease",35,0.343,3,0.00462,1,0.0568
"Globoid Cell Leukodystrophy",35,0.343,3,0.00462,1,0.0568
"Krabbe disease",35,0.343,3,0.00462,1,0.0568
"Metachromatic Leukodystrophy (MLD)",35,0.343,3,0.00462,1,0.0568
"Glycerophospholipid catabolism",11,0.108,2,0.00489,1,0.0596
"Gamma-glutamyl cycle for the biosynthesis and degradation of glutathione, including diseases",11,0.108,2,0.00489,1,0.0596
"Purine ribonucleoside monophosphate biosynthesis",36,0.353,3,0.00501,1,0.0606
"Sphingolipid de novo biosynthesis",36,0.353,3,0.00501,1,0.0606
"Degradation of cysteine and homocysteine",37,0.363,3,0.00541,1,0.0653
"Threonine catabolism",13,0.128,2,0.00684,1,0.0819
"Glutathione synthesis and recycling",13,0.128,2,0.00684,1,0.0819
"Serine biosynthesis",14,0.137,2,0.00794,1,0.0933
"Tyrosine catabolism",14,0.137,2,0.00794,1,0.0933
"Endothelin pathways",14,0.137,2,0.00794,1,0.0933
"Monoamine transport",14,0.137,2,0.00794,1,0.0933
"Sphingolipid metabolism in senescence",14,0.137,2,0.00794,1,0.0933
"Thyroxine biosynthesis",15,0.147,2,0.0091,1,0.104
"Choline catabolism",15,0.147,2,0.0091,1,0.104
"Serotonin and melatonin biosynthesis",15,0.147,2,0.0091,1,0.104
"5-Oxoprolinuria",15,0.147,2,0.0091,1,0.104
"Biotin metabolism, including IMDs",15,0.147,2,0.0091,1,0.104
"Linoleic acid metabolism affected by SARS-CoV-2",15,0.147,2,0.0091,1,0.104
"NAD+ biosynthetic pathways",15,0.147,2,0.0091,1,0.104
"Phase I - Functionalization of compounds",189,1.85,6,0.00952,1,0.109
"Nucleobase biosynthesis",46,0.451,3,0.00995,1,0.113
"Nucleotide biosynthesis",47,0.461,3,0.0106,1,0.12
"Nitric oxide stimulates guanylate cyclase",17,0.167,2,0.0116,1,0.131
"Biosynthesis of protectin and resolvin conjugates in tissue regeneration (PCTR and RCTR)",17,0.167,2,0.0116,1,0.131
"Molybdenum cofactor biosynthesis",18,0.177,2,0.013,1,0.146
"Starch and sucrose metabolism",52,0.51,3,0.0139,1,0.156
"Amino acid metabolism in triple-negative breast cancer cells",19,0.186,2,0.0145,1,0.16
"Vitamin B6-dependent and responsive disorders",19,0.186,2,0.0145,1,0.16
"7q11.23 copy number variation syndrome",19,0.186,2,0.0145,1,0.16
"Beta-oxidation of pristanoyl-CoA",20,0.196,2,0.016,1,0.176
"Recycling of bile acids and salts",20,0.196,2,0.016,1,0.176
"Vitamin B12 metabolism",55,0.54,3,0.0162,1,0.178
"Biosynthesis of DHA-derived sulfido conjugates",21,0.206,2,0.0175,1,0.192
"27-Hydroxylase Deficiency",58,0.569,3,0.0186,1,0.199
"Cerebrotendinous Xanthomatosis (CTX)",58,0.569,3,0.0186,1,0.199
"Congenital Bile Acid Synthesis Defect Type II",58,0.569,3,0.0186,1,0.199
"Congenital Bile Acid Synthesis Defect Type III",58,0.569,3,0.0186,1,0.199
"Familial Hypercholanemia (FHCA)",58,0.569,3,0.0186,1,0.199
"Zellweger Syndrome",58,0.569,3,0.0186,1,0.199
"Purine metabolism and related disorders",58,0.569,3,0.0186,1,0.199
"Histidine catabolism",22,0.216,2,0.0192,1,0.199
"Pyrimidine biosynthesis",22,0.216,2,0.0192,1,0.199
"2-aminoadipic 2-oxoadipic aciduria",22,0.216,2,0.0192,1,0.199
"Hyperlysinemia I, Familial",22,0.216,2,0.0192,1,0.199
"Hyperlysinemia II or Saccharopinuria",22,0.216,2,0.0192,1,0.199
"Pyridoxine dependency with seizures",22,0.216,2,0.0192,1,0.199
"Saccharopinuria/Hyperlysinemia II",22,0.216,2,0.0192,1,0.199
"MTHFR deficiency",22,0.216,2,0.0192,1,0.199
"Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway",22,0.216,2,0.0192,1,0.199
"Selenium micronutrient network",106,1.04,4,0.0193,1,0.199
"Primary bile acid biosynthesis",59,0.579,3,0.0195,1,0.199
"Presynaptic function of Kainate receptors",2,0.0196,1,0.0195,1,0.199
"Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25)",2,0.0196,1,0.0195,1,0.199
"Serotonin receptor 4/6/7 and NR3C signaling",2,0.0196,1,0.0195,1,0.199
"Serotonin and anxiety-related events",2,0.0196,1,0.0195,1,0.199
"Diseases of metabolism",162,1.59,5,0.02,1,0.204
"Alkaptonuria",60,0.589,3,0.0204,1,0.204
"Dopamine beta-hydroxylase deficiency",60,0.589,3,0.0204,1,0.204
"Hawkinsinuria",60,0.589,3,0.0204,1,0.204
"Monoamine oxidase-a deficiency (MAO-A)",60,0.589,3,0.0204,1,0.204
"Tyrosinemia Type I",60,0.589,3,0.0204,1,0.204
"Tyrosinemia, transient, of the newborn",60,0.589,3,0.0204,1,0.204
"Selenocompound metabolism",23,0.226,2,0.0209,1,0.207
"Krebs cycle disorders",23,0.226,2,0.0209,1,0.207
"Synthesis of ceramides and 1-deoxyceramides",23,0.226,2,0.0209,1,0.207
"Transport of vitamins, nucleosides, and related molecules",62,0.608,3,0.0222,1,0.219
"Signaling by Receptor Tyrosine Kinases",62,0.608,3,0.0222,1,0.219
"Lysine degradation",24,0.235,2,0.0226,1,0.219
"Anti-inflammatory response favouring Leishmania parasite infection",24,0.235,2,0.0226,1,0.219
"Leishmania parasite growth and survival",24,0.235,2,0.0226,1,0.219
"Oxidation of Branched Chain Fatty Acids",24,0.235,2,0.0226,1,0.219
"Tyrosine metabolism and related disorders",24,0.235,2,0.0226,1,0.219
"Sphingolipid pathway",24,0.235,2,0.0226,1,0.219
"Post-translational protein modification",169,1.66,5,0.0236,1,0.227
"Sphingolipid metabolism",64,0.628,3,0.0242,1,0.232
"PI Metabolism",25,0.245,2,0.0244,1,0.234
"Proximal tubule transport",25,0.245,2,0.0244,1,0.234
"Adenine phosphoribosyltransferase deficiency (APRT)",66,0.648,3,0.0262,1,0.241
"Adenosine Deaminase Deficiency",66,0.648,3,0.0262,1,0.241
"Adenylosuccinate Lyase Deficiency",66,0.648,3,0.0262,1,0.241
"AICA-Ribosiduria",66,0.648,3,0.0262,1,0.241
"Gout or Kelley-Seegmiller Syndrome",66,0.648,3,0.0262,1,0.241
"Lesch-Nyhan Syndrome (LNS)",66,0.648,3,0.0262,1,0.241
"Mitochondrial DNA depletion syndrome",66,0.648,3,0.0262,1,0.241
"Molybdenum Cofactor Deficiency",66,0.648,3,0.0262,1,0.241
"Myoadenylate deaminase deficiency",66,0.648,3,0.0262,1,0.241
"Purine Nucleoside Phosphorylase Deficiency",66,0.648,3,0.0262,1,0.241
"Xanthine Dehydrogenase Deficiency (Xanthinuria)",66,0.648,3,0.0262,1,0.241
"Xanthinuria type I",66,0.648,3,0.0262,1,0.241
"Xanthinuria type II",66,0.648,3,0.0262,1,0.241
"Long-chain-3-hydroxyacyl-coa dehydrogenase deficiency (LCHAD)",26,0.255,2,0.0263,1,0.242
"Purine metabolism",67,0.657,3,0.0272,1,0.249
"Selenoamino acid metabolism",67,0.657,3,0.0272,1,0.249
"GABA metabolism (aka GHB)",27,0.265,2,0.0282,1,0.256
"Tyrosine metabolism",68,0.667,3,0.0283,1,0.256
"Disulfiram Action Pathway",68,0.667,3,0.0283,1,0.256
"Metabolism of lipids",608,5.96,11,0.0287,1,0.256
"Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG)",3,0.0294,1,0.0292,1,0.256
"Activation of AMPA receptors",3,0.0294,1,0.0292,1,0.256
"Activation of Ca-permeable Kainate Receptor",3,0.0294,1,0.0292,1,0.256
"Activation of Na-permeable kainate receptors",3,0.0294,1,0.0292,1,0.256
"Defective SLC6A5 causes hyperekplexia 3 (HKPX3)",3,0.0294,1,0.0292,1,0.256
"UCH proteinases",3,0.0294,1,0.0292,1,0.256
"Defective GCLC causes HAGGSD",3,0.0294,1,0.0292,1,0.256
"Fas ligand pathway and stress induction of heat shock proteins",3,0.0294,1,0.0292,1,0.256
"Prader-Willi and Angelman syndrome",3,0.0294,1,0.0292,1,0.256
"Lac-Phe pathway",3,0.0294,1,0.0292,1,0.256
"Serotonin receptor 2 and ELK-SRF/GATA4 signaling",3,0.0294,1,0.0292,1,0.256
"Fatty Acid Elongation In Mitochondria",28,0.275,2,0.0302,1,0.264
"Kynurenine pathway and links to cell senescence",28,0.275,2,0.0302,1,0.264
"Aflatoxin activation and detoxification",29,0.285,2,0.0323,1,0.279
"Glutathione conjugation",29,0.285,2,0.0323,1,0.279
"Synthesis of Leukotrienes (LT) and Eoxins (EX)",29,0.285,2,0.0323,1,0.279
"Paracetamol ADME",30,0.294,2,0.0344,1,0.295
"Lysine catabolism",30,0.294,2,0.0344,1,0.295
"Metabolic reprogramming in pancreatic cancer",30,0.294,2,0.0344,1,0.295
"Gluconeogenesis",31,0.304,2,0.0365,1,0.31
"The oncogenic action of 2-hydroxyglutarate",31,0.304,2,0.0365,1,0.31
"The oncogenic action of D-2-hydroxyglutarate in  Hydroxygluaricaciduria",31,0.304,2,0.0365,1,0.31
"The oncogenic action of L-2-hydroxyglutarate in  Hydroxygluaricaciduria",31,0.304,2,0.0365,1,0.31
"GABA synthesis",4,0.0392,1,0.0387,1,0.318
"Phenylketonuria",4,0.0392,1,0.0387,1,0.318
"Oleoyl-phe metabolism",4,0.0392,1,0.0387,1,0.318
"Ionotropic activity of kainate receptors",4,0.0392,1,0.0387,1,0.318
"Activation of kainate receptors upon glutamate binding",4,0.0392,1,0.0387,1,0.318
"Defective GSS causes GSS deficiency",4,0.0392,1,0.0387,1,0.318
"Defective MAOA causes BRUNS",4,0.0392,1,0.0387,1,0.318
"Proton/oligopeptide cotransporters",4,0.0392,1,0.0387,1,0.318
"Methylhistidine Metabolism",4,0.0392,1,0.0387,1,0.318
"Common pathways underlying drug addiction",4,0.0392,1,0.0387,1,0.318
"Parkinson's disease pathway",4,0.0392,1,0.0387,1,0.318
"15q13.3 copy number variation syndrome",4,0.0392,1,0.0387,1,0.318
"TNF-alpha signaling pathway",4,0.0392,1,0.0387,1,0.318
"Mercaptopurine Action Pathway",80,0.785,3,0.0428,1,0.349
"Histidine metabolism",34,0.334,2,0.0432,1,0.349
"Propanoate metabolism",34,0.334,2,0.0432,1,0.349
"Histidinemia",34,0.334,2,0.0432,1,0.349
"Malonic Aciduria",34,0.334,2,0.0432,1,0.349
"Malonyl-coa decarboxylase deficiency",34,0.334,2,0.0432,1,0.349
"Methylmalonic Aciduria Due to Cobalamin-Related Disorders",34,0.334,2,0.0432,1,0.349
"Metabolism of sphingolipids in ER and Golgi apparatus",34,0.334,2,0.0432,1,0.349
"Thioguanine Action Pathway",81,0.795,3,0.0442,1,0.355
"Hemostasis",82,0.804,3,0.0455,1,0.357
"Azathioprine Action Pathway",82,0.804,3,0.0455,1,0.357
"Platelet homeostasis",35,0.343,2,0.0456,1,0.357
"Carnitine palmitoyl transferase deficiency (I)",35,0.343,2,0.0456,1,0.357
"Carnitine palmitoyl transferase deficiency (II)",35,0.343,2,0.0456,1,0.357
"Ethylmalonic Encephalopathy",35,0.343,2,0.0456,1,0.357
"Glutaric Aciduria Type I",35,0.343,2,0.0456,1,0.357
"Long chain acyl-CoA dehydrogenase deficiency (LCAD)",35,0.343,2,0.0456,1,0.357
"Medium chain acyl-coa dehydrogenase deficiency (MCAD)",35,0.343,2,0.0456,1,0.357
"Short Chain Acyl CoA Dehydrogenase Deficiency (SCAD Deficiency)",35,0.343,2,0.0456,1,0.357
"Trifunctional protein deficiency",35,0.343,2,0.0456,1,0.357
"Very-long-chain acyl coa dehydrogenase deficiency (VLCAD)",35,0.343,2,0.0456,1,0.357
"Sensory Perception",203,1.99,5,0.0467,1,0.364
"Fatty acid Metabolism",36,0.353,2,0.048,1,0.369
"Biotin Metabolism",5,0.0491,1,0.0481,1,0.369
"Defective MAT1A causes MATD",5,0.0491,1,0.0481,1,0.369
"Serotonin Neurotransmitter Release Cycle",5,0.0491,1,0.0481,1,0.369
"Biotinidase Deficiency",5,0.0491,1,0.0481,1,0.369
"Multiple carboxylase deficiency, neonatal or early onset form",5,0.0491,1,0.0481,1,0.369
"Methylation pathways",5,0.0491,1,0.0481,1,0.369
"Gut-liver indole metabolism",5,0.0491,1,0.0481,1,0.369
"Mitochondrial beta-oxidation",142,1.39,4,0.049,1,0.375
"Cellular responses to stress",87,0.854,3,0.0527,1,0.402
"16p11.2 proximal deletion syndrome",39,0.383,2,0.0554,1,0.42
"Ferroptosis",39,0.383,2,0.0554,1,0.42
"Cellular responses to stimuli",89,0.873,3,0.0557,1,0.422
"Synthesis of PS",6,0.0589,1,0.0575,1,0.425
"Intracellular metabolism of fatty acids regulates insulin secretion",6,0.0589,1,0.0575,1,0.425
"Neurotransmitter uptake and metabolism In glial cells",6,0.0589,1,0.0575,1,0.425
"Astrocytic Glutamate-Glutamine Uptake And Metabolism",6,0.0589,1,0.0575,1,0.425
"Excitatory Neural Signalling Through 5-HTR 4 and Serotonin",6,0.0589,1,0.0575,1,0.425
"Excitatory Neural Signalling Through 5-HTR 6 and Serotonin",6,0.0589,1,0.0575,1,0.425
"Excitatory Neural Signalling Through 5-HTR 7 and Serotonin",6,0.0589,1,0.0575,1,0.425
"Fragile X syndrome",6,0.0589,1,0.0575,1,0.425
"Serotonin HTR1 group and FOS pathway",6,0.0589,1,0.0575,1,0.425
"MTOR signaling",6,0.0589,1,0.0575,1,0.425
"G alpha (i) signaling events",91,0.893,3,0.0588,1,0.434
"Class A/1 (Rhodopsin-like receptors)",154,1.51,4,0.0626,1,0.46
"Metabolism of nucleotides",154,1.51,4,0.0626,1,0.46
"Glucose metabolism",42,0.412,2,0.0632,1,0.464
"Sensory perception of sweet, bitter, and umami (glutamate) taste",94,0.922,3,0.0636,1,0.466
"Immune System",155,1.52,4,0.0638,1,0.466
"Hypusine synthesis from eIF5A-lysine",7,0.0687,1,0.0667,1,0.479
"RORA activates gene expression",7,0.0687,1,0.0667,1,0.479
"BMAL1:CLOCK,NPAS2 activates circadian gene expression",7,0.0687,1,0.0667,1,0.479
"Sensory processing of sound by inner hair cells of the cochlea",7,0.0687,1,0.0667,1,0.479
"Gamma-cystathionase deficiency (CTH)",7,0.0687,1,0.0667,1,0.479
"Homocystinuria, cystathionine beta-synthase deficiency",7,0.0687,1,0.0667,1,0.479
"Monoamine GPCRs",7,0.0687,1,0.0667,1,0.479
"Roles of ceramides in development of insulin resistance",7,0.0687,1,0.0667,1,0.479
"Glycerophospholipid biosynthesis",97,0.952,3,0.0686,1,0.489
"Leishmania infection",44,0.432,2,0.0686,1,0.489
"Parasitic Infection Pathways",44,0.432,2,0.0686,1,0.489
"Sensory perception of taste",98,0.961,3,0.0703,1,0.5
"ROS and RNS production in phagocytes",46,0.451,2,0.0742,1,0.524
"Cysteine formation from homocysteine",8,0.0785,1,0.0759,1,0.524
"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",8,0.0785,1,0.0759,1,0.524
"Activation of gene expression by SREBF (SREBP)",8,0.0785,1,0.0759,1,0.524
"Glutamate Neurotransmitter Release Cycle",8,0.0785,1,0.0759,1,0.524
"Glutamate binding, activation of AMPA receptors and synaptic plasticity",8,0.0785,1,0.0759,1,0.524
"Conjugation of salicylate with glycine",8,0.0785,1,0.0759,1,0.524
"Conjugation of benzoate with glycine",8,0.0785,1,0.0759,1,0.524
"Homocysteine Degradation",8,0.0785,1,0.0759,1,0.524
"Carfentanil Action Pathway",8,0.0785,1,0.0759,1,0.524
"Phosphatidylethanolamine Biosynthesis",8,0.0785,1,0.0759,1,0.524
"Acrylamide biotransformation and exposure biomarkers",8,0.0785,1,0.0759,1,0.524
"Glycolysis in senescence",8,0.0785,1,0.0759,1,0.524
"Nanoparticle triggered regulated necrosis",8,0.0785,1,0.0759,1,0.524
"Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol",47,0.461,2,0.077,1,0.531
"Phospholipid metabolism",105,1.03,3,0.0827,1,0.531
"Sphingolipid metabolism: integrated pathway",49,0.481,2,0.0827,1,0.531
"Biotin transport and metabolism",9,0.0883,1,0.085,1,0.531
"Scavenging by Class F Receptors",9,0.0883,1,0.085,1,0.531
"Hydrolysis of LPC",9,0.0883,1,0.085,1,0.531
"Degradation of GABA",9,0.0883,1,0.085,1,0.531
"MTOR signalling",9,0.0883,1,0.085,1,0.531
"3-Methylthiofentanyl Action Pathway",9,0.0883,1,0.085,1,0.531
"Alfentanil Action Pathway",9,0.0883,1,0.085,1,0.531
"Alvimopan Action Pathway",9,0.0883,1,0.085,1,0.531
"Anileridine Action Pathway",9,0.0883,1,0.085,1,0.531
"Benzocaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Bupivacaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Buprenorphine Action Pathway",9,0.0883,1,0.085,1,0.531
"Chloroprocaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Cocaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Dezocine Action Pathway",9,0.0883,1,0.085,1,0.531
"Dibucaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Dihydromorphine Action Pathway",9,0.0883,1,0.085,1,0.531
"Dimethylthiambutene Action Pathway",9,0.0883,1,0.085,1,0.531
"Diphenoxylate Action Pathway",9,0.0883,1,0.085,1,0.531
"Escitalopram Action Pathway",9,0.0883,1,0.085,1,0.531
"Ethylmorphine Action Pathway",9,0.0883,1,0.085,1,0.531
"Fentanyl Action Pathway",9,0.0883,1,0.085,1,0.531
"Hydrocodone Action Pathway",9,0.0883,1,0.085,1,0.531
"Hydromorphone Action Pathway",9,0.0883,1,0.085,1,0.531
"Ketobemidone  Action Pathway",9,0.0883,1,0.085,1,0.531
"Levallorphan Action Pathway",9,0.0883,1,0.085,1,0.531
"Levobupivacaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Levomethadyl Acetate Action Action Pathway",9,0.0883,1,0.085,1,0.531
"Levorphanol Action Pathway",9,0.0883,1,0.085,1,0.531
"Mepivacaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Methadyl Acetate Action Pathway",9,0.0883,1,0.085,1,0.531
"Nalbuphine Action Pathway",9,0.0883,1,0.085,1,0.531
"Naloxone Action Pathway",9,0.0883,1,0.085,1,0.531
"Naltrexone Action Pathway",9,0.0883,1,0.085,1,0.531
"Oxybuprocaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Oxycodone Action Pathway",9,0.0883,1,0.085,1,0.531
"Oxymorphone Action Pathway",9,0.0883,1,0.085,1,0.531
"Pentazocine Action Pathway",9,0.0883,1,0.085,1,0.531
"Prilocaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Procaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Proparacaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Propoxyphene Action Pathway",9,0.0883,1,0.085,1,0.531
"Remifentanil Action Pathway",9,0.0883,1,0.085,1,0.531
"Ropivacaine Action Pathway",9,0.0883,1,0.085,1,0.531
"Sufentanil Action Pathway",9,0.0883,1,0.085,1,0.531
"Tramadol Action Action Pathway",9,0.0883,1,0.085,1,0.531
"Nicotine effect on dopaminergic neurons",9,0.0883,1,0.085,1,0.531
"GPCRs, class A rhodopsin-like",9,0.0883,1,0.085,1,0.531
"G alpha (i) signalling events",108,1.06,3,0.0883,1,0.55
"Glycine degradation",10,0.0981,1,0.094,1,0.572
"Proline catabolism",10,0.0981,1,0.094,1,0.572
"L1CAM interactions",10,0.0981,1,0.094,1,0.572
"Sensory processing of sound",10,0.0981,1,0.094,1,0.572
"Metabolism of serotonin",10,0.0981,1,0.094,1,0.572
"Deubiquitination",10,0.0981,1,0.094,1,0.572
"Serotonin receptors",10,0.0981,1,0.094,1,0.572
"Role of carnosine in muscle contraction",10,0.0981,1,0.094,1,0.572
"Acetylcholine synthesis",10,0.0981,1,0.094,1,0.572
"Amino acid conjugation of benzoic acid",10,0.0981,1,0.094,1,0.572
"GABA receptor signaling",10,0.0981,1,0.094,1,0.572
"Modulation of PI3K-Akt-mTOR signaling by bioactive sphingolipids",10,0.0981,1,0.094,1,0.572
"Farnesyl to CoQ10 metabolism",10,0.0981,1,0.094,1,0.572
"Biosynthesis of DHA-derived SPMs",55,0.54,2,0.101,1,0.61
"Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB",11,0.108,1,0.103,1,0.61
"Regulation of cholesterol biosynthesis by SREBP (SREBF)",11,0.108,1,0.103,1,0.61
"Keratinization",11,0.108,1,0.103,1,0.61
"Formation of the cornified envelope",11,0.108,1,0.103,1,0.61
"Mitochondrial iron-sulfur cluster biogenesis",11,0.108,1,0.103,1,0.61
"The retinoid cycle in cones (daylight vision)",11,0.108,1,0.103,1,0.61
"Transcriptional regulation of white adipocyte differentiation",11,0.108,1,0.103,1,0.61
"Plasmalogen biosynthesis",11,0.108,1,0.103,1,0.61
"Platelet degranulation",11,0.108,1,0.103,1,0.61
"Heroin Action Pathway",11,0.108,1,0.103,1,0.61
"NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence",11,0.108,1,0.103,1,0.61
"Sebaleic acid formation and metabolism",11,0.108,1,0.103,1,0.61
"Response to elevated platelet cytosolic Ca ions",11,0.108,1,0.103,1,0.61
"Taurine and Hypotaurine Metabolism",12,0.118,1,0.112,1,0.652
"Mitochondrial Uncoupling",12,0.118,1,0.112,1,0.652
"Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion",12,0.118,1,0.112,1,0.652
"Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA",12,0.118,1,0.112,1,0.652
"Serotonin clearance from the synaptic cleft",12,0.118,1,0.112,1,0.652
"Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA",12,0.118,1,0.112,1,0.652
"Thyroid hormone synthesis",12,0.118,1,0.112,1,0.652
"Disorders in ketone body synthesis",12,0.118,1,0.112,1,0.652
"Thyroxine (thyroid hormone) production",12,0.118,1,0.112,1,0.652
"Peroxisomal lipid metabolism",59,0.579,2,0.113,1,0.66
"Acyl chain remodelling of PE",13,0.128,1,0.12,1,0.69
"Response to elevated platelet cytosolic Ca2+",13,0.128,1,0.12,1,0.69
"Adrenoleukodystrophy, X-linked",13,0.128,1,0.12,1,0.69
"Carnitine-acylcarnitine translocase deficiency",13,0.128,1,0.12,1,0.69
"Lipid metabolism pathway",13,0.128,1,0.12,1,0.69
"Folate-alcohol and cancer pathway hypotheses",13,0.128,1,0.12,1,0.69
"Pluripotent stem cell differentiation pathway",13,0.128,1,0.12,1,0.69
"Phosphodiesterases in neuronal function",13,0.128,1,0.12,1,0.69
"NAD+ metabolism",13,0.128,1,0.12,1,0.69
"Vitamin K metabolism and activation of dependent proteins",13,0.128,1,0.12,1,0.69
"Innate Immune System",124,1.22,3,0.121,1,0.69
"Circadian Clock",14,0.137,1,0.129,1,0.729
"Organic anion transporters",14,0.137,1,0.129,1,0.729
"Desipramine Action Pathway",14,0.137,1,0.129,1,0.729
"Methadone Action Pathway",14,0.137,1,0.129,1,0.729
"Morphine Action Pathway",14,0.137,1,0.129,1,0.729
"Degradation pathway of sphingolipids, including diseases",14,0.137,1,0.129,1,0.729
"Disturbed pathways in Duchenne Muscular Dystrophy",14,0.137,1,0.129,1,0.729
"Visual phototransduction",64,0.628,2,0.13,1,0.731
"Scavenging by Class B Receptors",15,0.147,1,0.138,1,0.769
"Transcriptional activation of mitochondrial biogenesis",15,0.147,1,0.138,1,0.769
"Fluoxetine Action Pathway",15,0.147,1,0.138,1,0.769
"Vitamin D-sensitive calcium signaling in depression",15,0.147,1,0.138,1,0.769
"GPR143 in melanocytes and retinal pigment epithelium cells",15,0.147,1,0.138,1,0.769
"Vitamin B12 disorders",15,0.147,1,0.138,1,0.769
"Biosynthesis of unsaturated fatty acids",16,0.157,1,0.146,1,0.802
"GABA synthesis, release, reuptake and degradation",16,0.157,1,0.146,1,0.802
"Carnitine synthesis",16,0.157,1,0.146,1,0.802
"Regulation of TLR by endogenous ligand",16,0.157,1,0.146,1,0.802
"Mitochondrial biogenesis",16,0.157,1,0.146,1,0.802
"Amino Acid conjugation",16,0.157,1,0.146,1,0.802
"Conjugation of carboxylic acids",16,0.157,1,0.146,1,0.802
"Threonine and 2-Oxobutanoate Degradation",16,0.157,1,0.146,1,0.802
"Imipramine Action Pathway",16,0.157,1,0.146,1,0.802
"Biosynthesis and turnover of 1-deoxy-sphingoid bases",16,0.157,1,0.146,1,0.802
"Synthesis of bile acids and bile salts",71,0.697,2,0.153,1,0.829
"Glycerolipid Metabolism",17,0.167,1,0.155,1,0.829
"Digestion of dietary lipid",17,0.167,1,0.155,1,0.829
"Free fatty acids regulate insulin secretion",17,0.167,1,0.155,1,0.829
"PPARA activates gene expression",17,0.167,1,0.155,1,0.829
"Regulation of lipid metabolism by PPARalpha",17,0.167,1,0.155,1,0.829
"Wax and plasmalogen biosynthesis",17,0.167,1,0.155,1,0.829
"Aromatic L-Aminoacid Decarboxylase Deficiency",17,0.167,1,0.155,1,0.829
"Tyrosine hydroxylase deficiency",17,0.167,1,0.155,1,0.829
"Codeine Action Pathway",17,0.167,1,0.155,1,0.829
"D-glyceric acidura",17,0.167,1,0.155,1,0.829
"Familial lipoprotein lipase deficiency",17,0.167,1,0.155,1,0.829
"Glycerol Kinase Deficiency",17,0.167,1,0.155,1,0.829
"RAS and bradykinin pathways in COVID-19",17,0.167,1,0.155,1,0.829
"Bile acid and bile salt metabolism",72,0.706,2,0.157,1,0.839
"Methionine salvage pathway",18,0.177,1,0.163,1,0.864
"Triglyceride catabolism",18,0.177,1,0.163,1,0.864
"Heme signaling",18,0.177,1,0.163,1,0.864
"Catecholamine biosynthesis",18,0.177,1,0.163,1,0.864
"Glycolysis and gluconeogenesis",18,0.177,1,0.163,1,0.864
"Immunoregulatory interactions between lymphoid and non-lymphoid cells",18,0.177,1,0.163,1,0.864
"Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell",19,0.186,1,0.171,1,0.901
"Melatonin metabolism and effects",19,0.186,1,0.171,1,0.901
"Orexin receptor pathway",19,0.186,1,0.171,1,0.901
"Hemesynthesis defects and porphyrias",19,0.186,1,0.171,1,0.901
"Phase II - Conjugation of compounds",146,1.43,3,0.171,1,0.901
"Selenocysteine synthesis",20,0.196,1,0.179,1,0.935
"Synthesis of UDP-N-acetyl-glucosamine",20,0.196,1,0.179,1,0.935
"Mitochondrial Beta-Oxidation of Medium Chain Saturated Fatty Acids",20,0.196,1,0.179,1,0.935
"Lidocaine (Local Anaesthetic) Action Pathway",20,0.196,1,0.179,1,0.935
"Kennedy pathway from sphingolipids",20,0.196,1,0.179,1,0.935
"Mitochondrial fatty acid oxidation disorders",20,0.196,1,0.179,1,0.935
"Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane",21,0.206,1,0.187,1,0.966
"Beta-mercaptolactate-cysteine disulfiduria",21,0.206,1,0.187,1,0.966
"Cysteine Metabolism",21,0.206,1,0.187,1,0.966
"Cystinosis, ocular nonnephropathic",21,0.206,1,0.187,1,0.966
"Mitochondrial Beta-Oxidation of Short Chain Saturated Fatty Acids",21,0.206,1,0.187,1,0.966
"Cannabinoid receptor signaling",21,0.206,1,0.187,1,0.966
"Hereditary leiomyomatosis and renal cell carcinoma pathway",21,0.206,1,0.187,1,0.966
"One carbon pool by folate",22,0.216,1,0.195,1,0.997
"Inactivation, recovery and regulation of the phototransduction cascade",22,0.216,1,0.195,1,0.997
"Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty Acids",22,0.216,1,0.195,1,0.997
"Citalopram Action Pathway",22,0.216,1,0.195,1,0.997
"Folate malabsorption, hereditary",22,0.216,1,0.195,1,0.997
"Lactate shuttle in glial cells",22,0.216,1,0.195,1,0.997
"Thiamine metabolic pathways",22,0.216,1,0.195,1,0.997
"Metabolism of steroids",157,1.54,3,0.198,1,1
"HS-GAG degradation",23,0.226,1,0.203,1,1
"RAS processing",23,0.226,1,0.203,1,1
"Cobalamin (Cbl) metabolism",23,0.226,1,0.203,1,1
"Methotrexate Action Pathway",23,0.226,1,0.203,1,1
"Regucalcin in proximal tubule epithelial kidney cells",23,0.226,1,0.203,1,1
"TCA cycle (aka Krebs or citric acid cycle)",23,0.226,1,0.203,1,1
"Melanin biosynthesis",24,0.235,1,0.211,1,1
"Synthesis of wybutosine at G37 of tRNA(Phe)",24,0.235,1,0.211,1,1
"Organelle biogenesis and maintenance",24,0.235,1,0.211,1,1
"Phospholipid Biosynthesis",25,0.245,1,0.219,1,1
"Cytoprotection by HMOX1",25,0.245,1,0.219,1,1
"TP53 Regulates Metabolic Genes",25,0.245,1,0.219,1,1
"G(M2)-Gangliosidosis: Variant B, Tay-sachs disease",25,0.245,1,0.219,1,1
"Salla Disease/Infantile Sialic Acid Storage Disease",25,0.245,1,0.219,1,1
"Sialuria or French Type Sialuria",25,0.245,1,0.219,1,1
"Tay-Sachs Disease",25,0.245,1,0.219,1,1
"G alpha (s) signaling events",25,0.245,1,0.219,1,1
"Thermogenesis",25,0.245,1,0.219,1,1
"Cori cycle",25,0.245,1,0.219,1,1
"Citric Acid Cycle",26,0.255,1,0.227,1,1
"Synthesis of very long-chain fatty acyl-CoAs",26,0.255,1,0.227,1,1
"The phototransduction cascade",26,0.255,1,0.227,1,1
"2-ketoglutarate dehydrogenase complex deficiency",26,0.255,1,0.227,1,1
"Congenital lactic acidosis",26,0.255,1,0.227,1,1
"Fumarase deficiency",26,0.255,1,0.227,1,1
"Mitochondrial complex II deficiency",26,0.255,1,0.227,1,1
"Pyruvate dehydrogenase deficiency (E2)",26,0.255,1,0.227,1,1
"Pyruvate dehydrogenase deficiency (E3)",26,0.255,1,0.227,1,1
"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",27,0.265,1,0.234,1,1
"Sphingolipid metabolism overview",27,0.265,1,0.234,1,1
"Nicotinate and nicotinamide metabolism",28,0.275,1,0.242,1,1
"Triglyceride metabolism",28,0.275,1,0.242,1,1
"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",28,0.275,1,0.242,1,1
"Cobalamin (Cbl, vitamin B12) transport and metabolism",28,0.275,1,0.242,1,1
"Nicotine Action Pathway",28,0.275,1,0.242,1,1
"2q37 copy number variation syndrome",28,0.275,1,0.242,1,1
"Metabolism of Angiotensinogen to Angiotensins",29,0.285,1,0.249,1,1
"Enterocyte cholesterol metabolism",29,0.285,1,0.249,1,1
"G alpha (s) signalling events",30,0.294,1,0.257,1,1
"Scavenging by Class A Receptors",30,0.294,1,0.257,1,1
"The canonical retinoid cycle in rods (twilight vision)",30,0.294,1,0.257,1,1
"Gamma carboxylation, hypusine formation and arylsulfatase activation",31,0.304,1,0.264,1,1
"Neurotransmitter clearance",32,0.314,1,0.271,1,1
"Platelet activation, signaling and aggregation",32,0.314,1,0.271,1,1
"Heme biosynthesis",32,0.314,1,0.271,1,1
"The Oncogenic Action of Fumarate",32,0.314,1,0.271,1,1
"The Oncogenic Action of Succinate",32,0.314,1,0.271,1,1
"Cholesterol metabolism",32,0.314,1,0.271,1,1
"Heparan sulfate/heparin (HS-GAG) metabolism",33,0.324,1,0.279,1,1
"Retinoid metabolism and transport",33,0.324,1,0.279,1,1
"Dopamine metabolism",33,0.324,1,0.279,1,1
"Azathioprine ADME",34,0.334,1,0.286,1,1
"Amino Sugar Metabolism",35,0.343,1,0.293,1,1
"Aspirin ADME",35,0.343,1,0.293,1,1
"Glycosphingolipid metabolism",35,0.343,1,0.293,1,1
"Fatty acid beta-oxidation",35,0.343,1,0.293,1,1
"Drug ADME",110,1.08,2,0.294,1,1
"Porphyrin Metabolism",36,0.353,1,0.3,1,1
"Methylation",36,0.353,1,0.3,1,1
"Toll-like Receptor Cascades",36,0.353,1,0.3,1,1
"Acute Intermittent Porphyria",36,0.353,1,0.3,1,1
"Congenital Erythropoietic Porphyria (CEP) or Gunther Disease",36,0.353,1,0.3,1,1
"Hereditary Coproporphyria (HCP)",36,0.353,1,0.3,1,1
"Porphyria Variegata (PV)",36,0.353,1,0.3,1,1
"Regulation of insulin secretion",37,0.363,1,0.307,1,1
"Biosynthesis of specialized proresolving mediators (SPMs)",114,1.12,2,0.308,1,1
"Pyrimidine catabolism",39,0.383,1,0.32,1,1
"Transcriptional Regulation by TP53",39,0.383,1,0.32,1,1
"Binding and Uptake of Ligands by Scavenger Receptors",39,0.383,1,0.32,1,1
"mitochondrial fatty acid beta-oxidation of saturated fatty acids",39,0.383,1,0.32,1,1
"Fatty acyl-CoA biosynthesis",41,0.402,1,0.334,1,1
"Disorders of bile acid synthesis and biliary transport",41,0.402,1,0.334,1,1
"Cerivastatin Action Pathway",42,0.412,1,0.34,1,1
"Cholesteryl ester storage disease",42,0.412,1,0.34,1,1
"Desmosterolosis",42,0.412,1,0.34,1,1
"Hyper-IgD syndrome",42,0.412,1,0.34,1,1
"Hypercholesterolemia",42,0.412,1,0.34,1,1
"Lysosomal Acid Lipase Deficiency (Wolman Disease)",42,0.412,1,0.34,1,1
"Mevalonic aciduria",42,0.412,1,0.34,1,1
"Smith-Lemli-Opitz Syndrome (SLOS)",42,0.412,1,0.34,1,1
"Wolman disease",42,0.412,1,0.34,1,1
"Steroid Biosynthesis",43,0.422,1,0.347,1,1
"Metabolism of fat-soluble vitamins",43,0.422,1,0.347,1,1
"Digestion",43,0.422,1,0.347,1,1
"Alendronate Action Pathway",43,0.422,1,0.347,1,1
"Atorvastatin Action Pathway",43,0.422,1,0.347,1,1
"Ibandronate Action Pathway",43,0.422,1,0.347,1,1
"Lovastatin Action Pathway",43,0.422,1,0.347,1,1
"Pamidronate Action Pathway",43,0.422,1,0.347,1,1
"Pravastatin Action Pathway",43,0.422,1,0.347,1,1
"Risedronate Action Pathway",43,0.422,1,0.347,1,1
"Rosuvastatin Action Pathway",43,0.422,1,0.347,1,1
"Simvastatin Action Pathway",43,0.422,1,0.347,1,1
"Zoledronate Action Pathway",43,0.422,1,0.347,1,1
"Cellular response to chemical stress",44,0.432,1,0.353,1,1
"Fluvastatin Action Pathway",44,0.432,1,0.353,1,1
"Cholesterol metabolism with Bloch and Kandutsch-Russell pathways",44,0.432,1,0.353,1,1
"Digestion and absorption",45,0.441,1,0.36,1,1
"Integration of energy metabolism",45,0.441,1,0.36,1,1
"Metabolism of porphyrins",45,0.441,1,0.36,1,1
"Metabolism of cofactors",47,0.461,1,0.372,1,1
"Warburg Effect",47,0.461,1,0.372,1,1
"Interconversion of nucleotide di- and triphosphates",49,0.481,1,0.385,1,1
"Adaptive Immune System",53,0.52,1,0.409,1,1
"Glycerophospholipid biosynthetic pathway",54,0.53,1,0.415,1,1
"Metabolism of carbohydrates",146,1.43,2,0.423,1,1
"Nicotinate metabolism",56,0.549,1,0.426,1,1
"Generic Transcription Pathway",58,0.569,1,0.438,1,1
"Glycosaminoglycan metabolism",58,0.569,1,0.438,1,1
"The citric acid (TCA) cycle and respiratory electron transport",58,0.569,1,0.438,1,1
"Leukotriene C4 Synthesis Deficiency",60,0.589,1,0.449,1,1
"Rofecoxib Action Pathway",60,0.589,1,0.449,1,1
"Salicylate-sodium Action Pathway",60,0.589,1,0.449,1,1
"Trisalicylate-choline Action Pathway",60,0.589,1,0.449,1,1
"Acetaminophen  Action Pathway",61,0.598,1,0.454,1,1
"Acetylsalicylic Acid Action Pathway",61,0.598,1,0.454,1,1
"Antipyrine Action Pathway",61,0.598,1,0.454,1,1
"Antrafenine Action Pathway",61,0.598,1,0.454,1,1
"Bromfenac Action Pathway",61,0.598,1,0.454,1,1
"Carprofen Action Pathway",61,0.598,1,0.454,1,1
"Diflunisal Action Pathway",61,0.598,1,0.454,1,1
"Etodolac Action Pathway",61,0.598,1,0.454,1,1
"Etoricoxib Action Pathway",61,0.598,1,0.454,1,1
"Fenoprofen Action Pathway",61,0.598,1,0.454,1,1
"Flurbiprofen Action Pathway",61,0.598,1,0.454,1,1
"Indomethacin Action Pathway",61,0.598,1,0.454,1,1
"Ketoprofen Action Pathway",61,0.598,1,0.454,1,1
"Ketorolac Action Pathway",61,0.598,1,0.454,1,1
"Lornoxicam Action Pathway",61,0.598,1,0.454,1,1
"Lumiracoxib Action Pathway",61,0.598,1,0.454,1,1
"Magnesium salicylate Action Pathway",61,0.598,1,0.454,1,1
"Mefenamic Acid Action Pathway",61,0.598,1,0.454,1,1
"Meloxicam Action Pathway",61,0.598,1,0.454,1,1
"Nabumetone Action Pathway",61,0.598,1,0.454,1,1
"Nepafenac Action Pathway",61,0.598,1,0.454,1,1
"Oxaprozin Action Pathway",61,0.598,1,0.454,1,1
"Phenylbutazone Action Pathway",61,0.598,1,0.454,1,1
"Salicylic Acid Action Pathway",61,0.598,1,0.454,1,1
"Salsalate Action Pathway",61,0.598,1,0.454,1,1
"Sulindac Action Pathway",61,0.598,1,0.454,1,1
"Suprofen Action Pathway",61,0.598,1,0.454,1,1
"Tenoxicam Action Pathway",61,0.598,1,0.454,1,1
"Tiaprofenic Acid Action Pathway",61,0.598,1,0.454,1,1
"Tolmetin Action Pathway",61,0.598,1,0.454,1,1
"Valdecoxib Action Pathway",61,0.598,1,0.454,1,1
"Diclofenac Action Pathway",62,0.608,1,0.46,1,1
"Naproxen Action Pathway",62,0.608,1,0.46,1,1
"Piroxicam Action Pathway",62,0.608,1,0.46,1,1
"Arachidonic Acid Metabolism",63,0.618,1,0.465,1,1
"Vesicle-mediated transport",63,0.618,1,0.465,1,1
"Mitochondrial Fatty Acid Beta-Oxidation",63,0.618,1,0.465,1,1
"Synthesis of substrates in N-glycan biosythesis",64,0.628,1,0.47,1,1
"Amine ligand-binding receptors",65,0.638,1,0.476,1,1
"RNA Polymerase II Transcription",66,0.648,1,0.481,1,1
"Celecoxib Action Pathway",66,0.648,1,0.481,1,1
"Ibuprofen Action Pathway",69,0.677,1,0.496,1,1
"tRNA modification in the nucleus and cytosol",77,0.755,1,0.535,1,1
"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein",77,0.755,1,0.535,1,1
"Gene expression (Transcription)",79,0.775,1,0.544,1,1
"tRNA processing",84,0.824,1,0.567,1,1
"Infectious disease",195,1.91,2,0.577,1,1
"Nucleobase catabolism",101,0.991,1,0.635,1,1
"Nucleotide catabolism",104,1.02,1,0.646,1,1
"Metabolism of RNA",106,1.04,1,0.653,1,1
"Asparagine N-linked glycosylation",109,1.07,1,0.663,1,1
